Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Griguolo

Showing results (101-110 of 131) with videos related to

Pageof 14
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 26, 2021
Independent Validation of the PAM50-Based Chemo-Endocrine Score (CES) in Hormone Receptor-Positive HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2-Based TherapyTomás Pascual, Aranzazu Fernandez-Martinez, Maki Tanioka, et al.
NPJ Precision Oncology|March 20, 2021
Immune microenvironment characterisation and dynamics during anti-HER2-based neoadjuvant treatment in HER2-positive breast cancerG Griguolo, G Serna, T Pascual, et al.
Leukemia Research|October 12, 2018
Safety and efficacy of switching from branded to generic imatinib in chronic phase chronic myeloid leukemia patients treated in ItalyMassimiliano Bonifacio, Luigi Scaffidi, Gianni Binotto, et al.
NPJ Breast Cancer|December 13, 2025
Real-world effectiveness of PARP inhibitors after CDK4/6 inhibitor therapy in BRCA-mutated HR-positive/HER2-negative advanced breast cancerEmma Zattarin, Antonio Marra, Antonella Palazzo, et al.
Cancers|April 23, 2022
Definition of High-Risk Early Hormone-Positive HER2-Negative Breast Cancer: A Consensus ReviewMattia Garutti, Gaia Griguolo, Andrea Botticelli, et al.
Nature Communications|January 22, 2020
Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockadeFara Brasó-Maristany, Gaia Griguolo, Tomás Pascual, et al.
Breast (Edinburgh, Scotland)|May 8, 2023
Intrathecal trastuzumab versus alternate routes of delivery for HER2-targeted therapies in patients with HER2+ breast cancer leptomeningeal metastasesAnna-Maria Lazaratos, Sarah M Maritan, Andrea Quaiattini, et al.
Journal of the National Cancer Institute|December 28, 2022
HER2DX ERBB2 mRNA expression in advanced HER2-positive breast cancer treated with T-DM1Fara Brasó-Maristany, Gaia Griguolo, Nuria Chic, et al.
Cancers|July 18, 2020
<i>ERBB2</i> mRNA Expression and Response to Ado-Trastuzumab Emtansine (T-DM1) in HER2-Positive Breast CancerGaia Griguolo, Fara Brasó-Maristany, Blanca González-Farré, et al.
ESMO Open|April 5, 2021
T-DM1 versus pertuzumab, trastuzumab and a taxane as first-line therapy of early-relapsed HER2-positive metastatic breast cancer: an Italian multicenter observational studyF Schettini, B Conte, G Buono, et al.
Pageof 14

Showing results (101-110 of 131) with videos related to

Sort By:
Pageof 14
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 26, 2021
Independent Validation of the PAM50-Based Chemo-Endocrine Score (CES) in Hormone Receptor-Positive HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2-Based TherapyTomás Pascual, Aranzazu Fernandez-Martinez, Maki Tanioka, et al.
NPJ Precision Oncology|March 20, 2021
Immune microenvironment characterisation and dynamics during anti-HER2-based neoadjuvant treatment in HER2-positive breast cancerG Griguolo, G Serna, T Pascual, et al.
Leukemia Research|October 12, 2018
Safety and efficacy of switching from branded to generic imatinib in chronic phase chronic myeloid leukemia patients treated in ItalyMassimiliano Bonifacio, Luigi Scaffidi, Gianni Binotto, et al.
NPJ Breast Cancer|December 13, 2025
Real-world effectiveness of PARP inhibitors after CDK4/6 inhibitor therapy in BRCA-mutated HR-positive/HER2-negative advanced breast cancerEmma Zattarin, Antonio Marra, Antonella Palazzo, et al.
Cancers|April 23, 2022
Definition of High-Risk Early Hormone-Positive HER2-Negative Breast Cancer: A Consensus ReviewMattia Garutti, Gaia Griguolo, Andrea Botticelli, et al.
Nature Communications|January 22, 2020
Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockadeFara Brasó-Maristany, Gaia Griguolo, Tomás Pascual, et al.
Breast (Edinburgh, Scotland)|May 8, 2023
Intrathecal trastuzumab versus alternate routes of delivery for HER2-targeted therapies in patients with HER2+ breast cancer leptomeningeal metastasesAnna-Maria Lazaratos, Sarah M Maritan, Andrea Quaiattini, et al.
Journal of the National Cancer Institute|December 28, 2022
HER2DX ERBB2 mRNA expression in advanced HER2-positive breast cancer treated with T-DM1Fara Brasó-Maristany, Gaia Griguolo, Nuria Chic, et al.
Cancers|July 18, 2020
<i>ERBB2</i> mRNA Expression and Response to Ado-Trastuzumab Emtansine (T-DM1) in HER2-Positive Breast CancerGaia Griguolo, Fara Brasó-Maristany, Blanca González-Farré, et al.
ESMO Open|April 5, 2021
T-DM1 versus pertuzumab, trastuzumab and a taxane as first-line therapy of early-relapsed HER2-positive metastatic breast cancer: an Italian multicenter observational studyF Schettini, B Conte, G Buono, et al.
Pageof 14